{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:09:33Z","timestamp":1790806173382,"version":"4.1.0"},"reference-count":571,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.rmr.2022.01.014","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T08:03:48Z","timestamp":1655885028000},"page":"e35-e106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique\u00a0\u2013\u00a0Actualisation 2021. Version int\u00e9grale"],"prefix":"10.1016","volume":"39","author":[{"given":"V.","family":"Cottin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jouneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marchand-Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"W\u00e9meau-Stervinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bergot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Borie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chenivesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gondouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hirschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lebargy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-H.","family":"Marquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pr\u00e9vot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Quetant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Trumbic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-Y.","family":"Brillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chalabreysse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chatt\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Fourrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kambouchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Le Guillou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Lhuillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mehdaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Naccache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paganon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"R\u00e9my-Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Si-Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Terrioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2022.01.014_bib1000","doi-asserted-by":"crossref","first-page":"1602419","DOI":"10.1183\/13993003.02419-2016","article-title":"Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris","volume":"50","author":"Duchemann","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1005","series-title":"Centre de r\u00e9f\u00e9rence des maladies pulmonaires rares","year":"2015"},{"key":"10.1016\/j.rmr.2022.01.014_bib1010","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.rmr.2017.07.017","article-title":"Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique\u2013Actualisation 2017","volume":"34","author":"Cottin","year":"2017","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2022.01.014_bib1015","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis","volume":"174","author":"Raghu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65\u00a0years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0025-6196(11)62955-8","article-title":"Idiopathic pulmonary fibrosis in patients younger than 50\u00a0years","volume":"80","author":"Nadrous","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rmr.2022.01.014_bib1030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mrfmmm.2011.10.013","article-title":"Telomerase and idiopathic pulmonary fibrosis","volume":"730","author":"Armanios","year":"2012","journal-title":"Mutat Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib1035","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/09031936.00217614","article-title":"Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry","volume":"46","author":"Behr","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/CLEP.S54815","article-title":"Epidemiology of idiopathic pulmonary fibrosis","volume":"5","author":"Ley","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1045","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: an International Working Group Report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1055","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.rmr.2013.09.007","volume":"30","author":"Cottin","year":"2013","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2022.01.014_bib1060","series-title":"M\u00e9thode \u00ab\u00a0Recommandations pour la pratique clinique\u00a0\u00bb","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2010"},{"key":"10.1016\/j.rmr.2022.01.014_bib1065","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1136\/thx.2006.062836","article-title":"Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK","volume":"61","author":"Gribbin","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1070","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1183\/09031936.06.00037005","article-title":"High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis","volume":"27","author":"Raghu","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1075","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1183\/09031936.00001612","article-title":"Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis?","volume":"40","author":"Cottin","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1080","doi-asserted-by":"crossref","first-page":"e2573","DOI":"10.1097\/MD.0000000000002573","article-title":"Auscultation of Velcro crackles is associated with usual interstitial pneumonia","volume":"95","author":"Sellares","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rmr.2022.01.014_bib1085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12890-018-0670-0","article-title":"Velcro-type\u201d crackles predict specific radiologic features of fibrotic interstitial lung disease","volume":"18","author":"Sgalla","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.rmed.2017.10.021","article-title":"Clubbing in patients with fibrotic interstitial lung diseases","volume":"132","author":"van Manen","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1095","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000490355","article-title":"The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients","volume":"96","author":"Nakatsuka","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib1100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1110","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1148\/radiol.12112516","article-title":"Interobserver variability in the CT assessment of honeycombing in the lungs","volume":"266","author":"Watadani","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/thoraxjnl-2015-207252","article-title":"Interobserver agreement for the ATS\/ERS\/JRS\/ALAT criteria for a UIP pattern on CT","volume":"71","author":"Walsh","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1164\/rccm.201907-1324ED","article-title":"The 2018\u00a0Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory","volume":"200","author":"Raghu","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1125","first-page":"210","article-title":"Crit\u00e8res de qualit\u00e9 du scanner thoracique r\u00e9alis\u00e9 pour une pneumopathie infiltrante diffuse","volume":"23","author":"R\u00e9my-Jardin","year":"2020","journal-title":"La Lettre du Pneumologue"},{"key":"10.1016\/j.rmr.2022.01.014_bib1130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner Society: glossary of terms for thoracic imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1164\/rccm.200412-1756OC","article-title":"High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis","volume":"172","author":"Lynch","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1140","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2214\/AJR.07.3177","article-title":"Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: effect of predominance and distribution of findings","volume":"191","author":"Sundaram","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1145","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s00330-012-2427-0","article-title":"Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants","volume":"22","author":"Walsh","year":"2012","journal-title":"Eur Radiol."},{"key":"10.1016\/j.rmr.2022.01.014_bib1150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1155","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00330-011-2098-2","article-title":"Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality","volume":"21","author":"Edey","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.200611-1696OC","article-title":"Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival","volume":"177","author":"Sumikawa","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1148\/radiology.189.3.8234692","article-title":"Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation","volume":"189","author":"Remy-Jardin","year":"1993","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1170","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.200709-1365OC","article-title":"Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis","volume":"178","author":"Akira","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1175","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1180","first-page":"299","article-title":"Pneumopathies interstitielles diffuses idiopathiques","volume":"21","author":"Cottin","year":"2004","journal-title":"Classification de Consensus International Multidisciplinaire de l\u2019American Thoracic Society et de l\u2019European Respiratory Society, principales entit\u00e9s anatomo-cliniques, et conduite du diagnostic. Rev Mal Respir"},{"key":"10.1016\/j.rmr.2022.01.014_bib1185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1148\/radiology.211.2.r99ma01555","article-title":"Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129\u00a0patients","volume":"211","author":"Johkoh","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1164\/ajrccm.164.2.2101090","article-title":"Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis","volume":"164","author":"Hunninghake","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1195","first-page":"171111","article-title":"Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography","author":"Mathieson","year":"1989","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1148\/radiology.205.1.9314990","article-title":"Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung","volume":"205","author":"Swensen","year":"1997","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1205","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1378\/chest.116.5.1168","article-title":"The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study","volume":"116","author":"Raghu","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1210","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1378\/chest.124.4.1215","article-title":"Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia","volume":"124","author":"Hunninghake","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1215","doi-asserted-by":"crossref","first-page":"W458","DOI":"10.2214\/AJR.12.9437","article-title":"UIP diagnosed at surgical lung biopsy, 2000-2009: HRCT patterns and proposed classification system","volume":"200","author":"Gruden","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1220","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/thx.2010.137190","article-title":"Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease","volume":"66","author":"Tcherakian","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1225","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2214\/AJR.04.1663","article-title":"Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206\u00a0patients","volume":"186","author":"Souza","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1230","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1164\/rccm.201804-0761OC","article-title":"Prognosticating outcomes in interstitial lung disease by mediastinal lymph node assessment. An observational cohort study with independent validation","volume":"199","author":"Adegunsoye","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1148\/radiol.2017152419","article-title":"Diffuse pulmonary ossification in fibrosing interstitial lung diseases: prevalence and associations","volume":"284","author":"Egashira","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1240","doi-asserted-by":"crossref","first-page":"101009","DOI":"10.1016\/j.eclinm.2021.101009","article-title":"Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment","volume":"38","author":"Gudmundsson","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.rmr.2022.01.014_bib1245","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1378\/chest.14-0976","article-title":"CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis","volume":"147","author":"Chung","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.rmed.2016.07.016","article-title":"Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling","volume":"118","author":"Salisbury","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1255","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/thoraxjnl-2016-209671","article-title":"The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia","volume":"72","author":"Brownell","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1265","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1270","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/13993003.01680-2015","article-title":"Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia","volume":"47","author":"Yagihashi","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1275","doi-asserted-by":"crossref","first-page":"1900531","DOI":"10.1183\/13993003.00531-2019","article-title":"Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis","volume":"54","author":"Barnett","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1280","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201508-1632OC","article-title":"In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States","volume":"193","author":"Hutchinson","year":"2016","journal-title":"2000\u00a0to 2011. Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1285","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1183\/13993003.00378-2016","article-title":"Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008","volume":"48","author":"Hutchinson","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1290","doi-asserted-by":"crossref","first-page":"1801164","DOI":"10.1183\/13993003.01164-2018","article-title":"Procedure volume and mortality after surgical lung biopsy in interstitial lung disease","volume":"53","author":"Fisher","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1295","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/resp.13223","article-title":"Diagnostic utility of surgical lung biopsies in elderly patients with indeterminate interstitial lung disease","volume":"23","author":"Vaszar","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1300","first-page":"115","article-title":"Video-assisted thoracoscopic lung biopsy in the diagnosis of diffuse interstitial lung disease. A prospective study","volume":"44","author":"Ayed","year":"2003","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.rmr.2022.01.014_bib1305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1749-8090-9-45","article-title":"The efficacy of video-assisted thoracoscopic surgery lung biopsies in patients with Interstitial Lung Disease: a retrospective study of 66\u00a0patients","volume":"9","author":"Morris","year":"2014","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1310","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0218492315593694","article-title":"Efficacy of minimally invasive surgery in diagnosis of interstitial lung disease","volume":"23","author":"Bagheri","year":"2015","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"10.1016\/j.rmr.2022.01.014_bib1315","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/LBR.0b013e3181b767cc","article-title":"Risk of acute exacerbation after video-assisted thoracoscopic lung biopsy for interstitial lung disease","volume":"16","author":"Bando","year":"2009","journal-title":"J Bronchology Interv Pulmonol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1320","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/icvts\/ivt217","article-title":"The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK","volume":"17","author":"Blackhall","year":"2013","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1325","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rppneu.2012.11.003","article-title":"Surgical lung biopsy for diffuse lung disease","volume":"19","author":"Blanco","year":"2013","journal-title":"Our experience in the last 15\u00a0years. Rev Port Pneumol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1330","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0003-4975(00)02657-6","article-title":"Open lung biopsy as an outpatient procedure","volume":"71","author":"Blewett","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1335","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.arbres.2014.05.011","article-title":"Do the number and volume of surgical lung biopsies influence the diagnostic yield in interstitial lung disease?. A propensity score analysis","volume":"51","author":"Fibla","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1340","first-page":"204","article-title":"Is Surgical Biopsy Necessary for Diagnosis of Interstitial Lung Diseases: A Retrospective Clinical Study","volume":"5","author":"F\u0131nd\u0131kc\u0131o\u011flu","year":"2014","journal-title":"J Clin Anal Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1345","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0873-2159(15)30144-6","article-title":"Interstitial lung disease: diagnostic accuracy and safety of surgical lung biopsy","volume":"15","author":"Guerra","year":"2009","journal-title":"Rev Port Pneumol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1350","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1590\/S1806-37132009000300007","article-title":"Video-assisted thoracoscopy for the diagnosis of diffuse parenchymal lung disease","volume":"35","author":"Ishie","year":"2009","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1355","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.athoracsur.2013.04.065","article-title":"Surgical biopsy of suspected interstitial lung disease is superior to radiographic diagnosis","volume":"96","author":"Kayatta","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1360","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/0218492316665551","article-title":"Single versus multiple lung biopsies for suspected interstitial lung disease","volume":"24","author":"Khalil","year":"2016","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"10.1016\/j.rmr.2022.01.014_bib1365","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.athoracsur.2006.10.002","article-title":"Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease","volume":"83","author":"Kreider","year":"2007","journal-title":"Ann Thorac Surg."},{"key":"10.1016\/j.rmr.2022.01.014_bib1370","first-page":"283","article-title":"The diagnosis efficacy and safety of video-assisted thoracoscopy surgery (VATS) in undefined interstitial lung diseases: a retrospective study","volume":"5","author":"Luo","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib1375","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0003-4975(00)01913-5","article-title":"A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease","volume":"70","author":"Miller","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1380","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.hlc.2005.01.002","article-title":"VATS lung biopsy in suspected, diffuse interstitial lung disease provides diagnosis, and alters management strategies","volume":"14","author":"Ooi","year":"2005","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.rmr.2022.01.014_bib1385","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.athoracsur.2012.10.043","article-title":"Awake thoracoscopic biopsy of interstitial lung disease","volume":"95","author":"Pompeo","year":"2013","journal-title":"Ann Thorac Surg."},{"key":"10.1016\/j.rmr.2022.01.014_bib1390","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1010-7940(02)00021-0","article-title":"Does lung biopsy help patients with interstitial lung disease?","volume":"21","author":"Qureshi","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1395","first-page":"251","article-title":"Efficacy and safety of surgical lung biopsy for interstitial disease","volume":"32","author":"Rotolo","year":"2015","journal-title":"Experience of 161\u00a0consecutive patients from a single institution in Italy. Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib1400","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/0218492314550724","article-title":"Thoracoscopic lung biopsy in 285\u00a0patients with diffuse pulmonary disease","volume":"23","author":"Samejima","year":"2015","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"10.1016\/j.rmr.2022.01.014_bib1405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.athoracsur.2009.04.002","article-title":"Diagnostic surgical lung biopsies for suspected interstitial lung diseases: a retrospective study","volume":"88","author":"Sigurdsson","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1410","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11748-014-0383-0","article-title":"Videothoracoscopy-assisted surgical lung biopsy for interstitial lung diseases","volume":"62","author":"Sonobe","year":"2014","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib1415","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1164\/rccm.201504-0711OC","article-title":"Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis","volume":"193","author":"Tomassetti","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1420","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000444089","article-title":"Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature","volume":"91","author":"Ravaglia","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib1425","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1157\/13119537","article-title":"Diagnoses and diagnostic procedures in 500\u00a0consecutive patients with clinical suspicion of interstitial lung disease","volume":"44","author":"Morell","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1430","first-page":"1197","article-title":"Transbronchial Lung Cryobiopsy and Video-assisted Thoracoscopic Lung Biopsy in the Diagnosis of Diffuse Parenchymal Lung Disease. A Meta-analysis of Diagnostic Test Accuracy","volume":"14","author":"Iftikhar","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2022.01.014_bib1435","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1164\/rccm.201903-0493OC","article-title":"Diagnostic likelihood thresholds that define a working diagnosis of idiopathic pulmonary fibrosis","volume":"200","author":"Walsh","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1440","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000484055","article-title":"Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Goup on Safety and Utility and a Call for Standardization of the Procedure","volume":"95","author":"Hetzel","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib1445","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000203987","article-title":"Transbronchial cryobiopsy: a new tool for lung biopsies","volume":"78","author":"Babiak","year":"2009","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib1450","first-page":"e000443","article-title":"Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study","volume":"6","author":"Troy","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib1455","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000456671","article-title":"Transbronchial lung cryobiopsy in diffuse parenchymal lung disease: comparison between biopsy from 1\u00a0segment and biopsy from 2\u00a0segments - diagnostic yield and complications","volume":"93","author":"Ravaglia","year":"2017","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib1460","doi-asserted-by":"crossref","first-page":"891","DOI":"10.5858\/arpa.2016-0233-RA","article-title":"Transbronchial Cryobiopsy in Diffuse Lung Disease: Update for the Pathologist","volume":"141","author":"Colby","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1465","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chest.2016.09.028","article-title":"Utility of Transbronchial vs Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease","volume":"151","author":"Sheth","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1470","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/LBR.0000000000000246","article-title":"Comparison of Transbronchial and Cryobiopsies in Evaluation of Diffuse Parenchymal Lung Disease","volume":"23","author":"Ramaswamy","year":"2016","journal-title":"J Bronchology Interv Pulmonol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1475","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S2213-2600(15)00140-X","article-title":"Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data","volume":"3","author":"Kim","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1480","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1513\/AnnalsATS.201612-947OC","article-title":"Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning","volume":"14","author":"Pankratz","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2022.01.014_bib1485","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/LBR.0000000000000292","article-title":"Transbronchial Cryobiopsy in Interstitial Lung Disease: Are We on the Right Path?","volume":"23","author":"Cascante","year":"2016","journal-title":"J Bronchology Interv Pulmonol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1490","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/resp.12296","article-title":"Histological diagnosis of interstitial lung diseases by cryo-transbronchial biopsy","volume":"19","author":"Fruchter","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1495","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1471-2466-14-171","article-title":"Diagnostic yield of transbronchial cryobiopsy in non-neoplastic lung disease: a retrospective case series","volume":"14","author":"Griff","year":"2014","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1500","first-page":"2","article-title":"Validation of transbronchial cryobiopsy in interstitial lung disease - interim analysis of a prospective trial and critical review of the literature","volume":"33","author":"Hagmeyer","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib1505","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.arbr.2015.02.001","article-title":"Cryobiopsy in the diagnosis of diffuse interstitial lung disease: yield and cost-effectiveness analysis","volume":"51","author":"Hernandez-Gonzalez","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1510","doi-asserted-by":"crossref","first-page":"1274099","DOI":"10.1080\/20018525.2016.1274099","article-title":"Introduction of cryobiopsies in the diagnostics of interstitial lung diseases - experiences in a referral center","volume":"4","author":"Kronborg-White","year":"2017","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1515","doi-asserted-by":"crossref","first-page":"e78674","DOI":"10.1371\/journal.pone.0078674","article-title":"Bronchoscopic cryobiopsy for the diagnosis of diffuse parenchymal lung disease","volume":"8","author":"Kropski","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib1520","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/crj.12207","article-title":"Transbronchial lung biopsy: the pathologist's point of view","volume":"10","author":"Pourabdollah","year":"2016","journal-title":"Clin Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1525","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.chest.2016.09.002","article-title":"Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Disease: Retrospective Analysis of 74\u00a0Cases","volume":"151","author":"Ussavarungsi","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1530","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1164\/rccm.201504-0711OC","article-title":"Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis","volume":"193","author":"Tomassetti","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1535","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1164\/rccm.201810-1947OC","article-title":"Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases","volume":"199","author":"Romagnoli","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1540","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12931-020-01487-w","article-title":"Usefulness of surgical lung biopsies after cryobiopsies when pathological results are inconclusive or show a pattern suggestive of a nonspecific interstitial pneumonia","volume":"21","author":"Bondue","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib1545","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2213-2600(19)30342-X","article-title":"Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study","volume":"8","author":"Troy","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1550","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S2213-2600(19)30059-1","article-title":"Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study","volume":"7","author":"Raghu","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1555","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1164\/rccm.202003-0877OC","article-title":"Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia","volume":"203","author":"Richeldi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1560","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1378\/chest.129.5.1126","article-title":"Transbronchial biopsy in usual interstitial pneumonia","volume":"129","author":"Berbescu","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1565","doi-asserted-by":"crossref","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib1570","doi-asserted-by":"crossref","first-page":"104021","DOI":"10.1016\/j.lpm.2020.104021","article-title":"Diagnostic approach of fibrosing interstitial lung diseases of unknown origin","volume":"49","author":"Cottin","year":"2020","journal-title":"Presse Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1575","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1580","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1585","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2213-2600(13)70191-7","article-title":"Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study","volume":"1","author":"Morell","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1590","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.sult.2013.10.006","article-title":"Chronic hypersensitivity pneumonitis and pulmonary sarcoidosis: differentiation from usual interstitial pneumonia using high-resolution computed tomography","volume":"35","author":"Jeong","year":"2014","journal-title":"Semin Ultrasound CT MR."},{"key":"10.1016\/j.rmr.2022.01.014_bib1595","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1183\/09059180.00004914","article-title":"Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?","volume":"23","author":"Wuyts","year":"2014","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib1600","first-page":"801","article-title":"Interstitial Lung Disease in India","volume":"195","author":"Singh","year":"2017","journal-title":"Results of a Prospective Registry. Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1605","first-page":"690","article-title":"Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia","volume":"196","author":"Salisbury","year":"2017","journal-title":"Where We Stand and Where We Need to Go. Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1610","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201611-2201PP","article-title":"Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management","volume":"196","author":"Vasakova","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1615","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"Park","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1620","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1183\/09031936.00101506","article-title":"Interstitial lung disease: are we missing formes frustes of connective tissue disease?","volume":"28","author":"Cottin","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1625","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2214\/AJR.18.20967","article-title":"Findings of Microscopic Polyangiitis: A Japanese First Nationwide Prospective Cohort Study","volume":"213","author":"Suzuki","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1630","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.rmed.2008.04.023","article-title":"ANCA-associated lung fibrosis: analysis of 17\u00a0patients","volume":"102","author":"Foulon","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1635","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1640","first-page":"1242","article-title":"Plasma Surfactant Protein-D","volume":"194","author":"White","year":"2016","journal-title":"Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1645","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.rmed.2015.06.003","article-title":"Serum metalloproteinases 1\u00a0and 7\u00a0in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias","volume":"109","author":"Morais","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1650","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1655","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1660","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1164\/rccm.200808-1313OC","article-title":"Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis","volume":"179","author":"Ohshimo","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1665","first-page":"e36","article-title":"Diagnosis of Hypersensitivity Pneumonitis in Adults","volume":"202","author":"Raghu","year":"2020","journal-title":"An Official ATS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1670","doi-asserted-by":"crossref","first-page":"2000206","DOI":"10.1183\/13993003.00206-2020","article-title":"Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis","volume":"56","author":"Adderley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1675","doi-asserted-by":"crossref","first-page":"1901144","DOI":"10.1183\/13993003.01144-2019","article-title":"Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging pattern","volume":"54","author":"Tzilas","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1680","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3343\/alm.2015.35.2.220","article-title":"Clinical usefulness of bronchoalveolar lavage cellular analysis and lymphocyte subsets in diffuse interstitial lung diseases","volume":"35","author":"Lee","year":"2015","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1685","first-page":"435","article-title":"The Role of Bronchoalveolar Lavage in the Diagnosis of Idiopathic Pulmonary Fibrosis: An Investigation of the Relevance of the Protein Content","volume":"70","author":"Schildge","year":"2016","journal-title":"Pneumologie"},{"key":"10.1016\/j.rmr.2022.01.014_bib1690","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1183\/09031936.98.12051010","article-title":"Idiopathic nonspecific interstitial pneumonia\/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP","volume":"12","author":"Nagai","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1695","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12952-017-0069-0","article-title":"The diagnostic value of the bronchoalveolar lavage in interstitial lung diseases","volume":"16","author":"Efared","year":"2017","journal-title":"J Negat Results Biomed"},{"key":"10.1016\/j.rmr.2022.01.014_bib1700","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1183\/09031936.04.00101303","article-title":"Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases","volume":"24","author":"Welker","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1705","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.rmed.2006.06.003","article-title":"Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias","volume":"101","author":"Ryu","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1710","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.03.00105202","article-title":"BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia","volume":"22","author":"Veeraraghavan","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1715","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5603\/ARM.a2021.0012","article-title":"Risk factors for acute exacerbation following bronchoalveolar lavage in patients with suspected idiopathic pulmonary fibrosis: A retrospective cohort study","volume":"89","author":"Abe","year":"2021","journal-title":"Adv Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1720","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.rmr.2022.01.014_bib1725","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1001\/jama.2013.5827","article-title":"Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis","volume":"309","author":"Peljto","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2022.01.014_bib1730","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","article-title":"Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study","volume":"5","author":"Allen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1735","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1183\/13993003.00308-2016","article-title":"Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive","volume":"48","author":"Newton","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1740","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1183\/13993003.02115-2015","article-title":"Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis","volume":"48","author":"Borie","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1745","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1750","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa066157","article-title":"Telomerase mutations in families with idiopathic pulmonary fibrosis","volume":"356","author":"Armanios","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1755","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1164\/rccm.200408-1104OC","article-title":"Clinical and pathologic features of familial interstitial pneumonia","volume":"172","author":"Steele","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1760","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1378\/chest.11-2812","article-title":"High-resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia","volume":"142","author":"Lee","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1765","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1378\/chest.127.6.2034","article-title":"Familial idiopathic pulmonary fibrosis: clinical features and outcome","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1770","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.rmr.2014.07.017","article-title":"Fibroses pulmonaires familiales","volume":"32","author":"Borie","year":"2015","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2022.01.014_bib1775","doi-asserted-by":"crossref","first-page":"e10680","DOI":"10.1371\/journal.pone.0010680","article-title":"Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations","volume":"5","author":"Diaz de Leon","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib1780","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1164\/rccm.200804-550OC","article-title":"Telomere shortening in familial and sporadic pulmonary fibrosis","volume":"178","author":"Cronkhite","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1785","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.healun.2014.11.010","article-title":"Severe hematologic complications after lung transplantation in patients with telomerase complex mutations","volume":"34","author":"Borie","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.rmr.2022.01.014_bib1790","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(14)70124-9","article-title":"Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation","volume":"2","author":"Stuart","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1795","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1378\/chest.15-0077","article-title":"Running short on time: lung transplant evaluation for telomere-related pulmonary fibrosis","volume":"147","author":"Garcia","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1800","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.200906-0953OC","article-title":"Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort","volume":"182","author":"van Moorsel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1805","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jmedgenet-2016-103973","article-title":"Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine","volume":"54","author":"Spagnolo","year":"2017","journal-title":"Journal of medical genetics"},{"key":"10.1016\/j.rmr.2022.01.014_bib1810","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1378\/chest.10-2865","article-title":"Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations","volume":"140","author":"Diaz de Leon","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1815","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jcm5080066","article-title":"A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre","volume":"5","author":"Chaudhuri","year":"2016","journal-title":"J Clin Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1820","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1183\/09031936.00063706","article-title":"Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis","volume":"31","author":"Thomeer","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1825","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/resp.12850","article-title":"Clinical impact of the interstitial lung disease multidisciplinary service","volume":"21","author":"Jo","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1830","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1746-1596-7-160","article-title":"Diagnostic approach to interstitial pneumonias in a single centre: report on 88\u00a0cases","volume":"7","author":"Theegarten","year":"2012","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1835","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","article-title":"Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study","volume":"4","author":"Walsh","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1840","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.03.026","article-title":"Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938\u00a0cases","volume":"153","author":"De Sadeleer","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1845","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.201104-0668OC","article-title":"Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study","volume":"184","author":"Lamas","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1850","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12890-016-0179-3","article-title":"Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres","volume":"16","author":"Jo","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1855","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.chest.2018.05.044","article-title":"Should Patients With Interstitial Lung Disease Be Seen by Experts?","volume":"154","author":"Cottin","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1860","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-016-0562-1","article-title":"Any fool can make a rule and any fool will mind it\u201d","volume":"14","author":"Wells","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1865","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/resp.12568","article-title":"Unclassifiable interstitial lung disease: A review","volume":"21","author":"Skolnik","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1870","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0000000000000509","article-title":"Unclassifiable interstitial lung disease: from phenotyping to possible treatments","volume":"24","author":"Guler","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1875","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1513\/AnnalsATS.201801-067OC","article-title":"Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2022.01.014_bib1880","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1183\/09031936.00131912","article-title":"Prevalence and prognosis of unclassifiable interstitial lung disease","volume":"42","author":"Ryerson","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1885","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/resp.12931","article-title":"Unclassifiable interstitial lung diseases: Clinical characteristics and survival","volume":"22","author":"Hyldgaard","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1890","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1164\/rccm.201702-0400PP","article-title":"A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective","volume":"196","author":"Ryerson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1895","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.rmed.2003.10.015","article-title":"Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment","volume":"98","author":"Thomeer","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1900","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rmed.2017.07.007","article-title":"Unclassifiable-interstitial lung disease: outcome prediction using CT and functional indices","volume":"130","author":"Jacob","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1905","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"18","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1910","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/thoraxjnl-2019-213620","article-title":"Risk factors for disease progression in idiopathic pulmonary fibrosis","volume":"75","author":"Raghu","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1915","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","article-title":"Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1920","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000496735","article-title":"A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT","volume":"98","author":"Jouneau","year":"2019","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib1925","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nut.2018.12.008","article-title":"What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center","volume":"62","author":"Jouneau","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.rmr.2022.01.014_bib1930","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12931-020-01528-4","article-title":"Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis","volume":"21","author":"Jouneau","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib1935","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1940","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/09031936.00146314","article-title":"Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis","volume":"45","author":"Ley","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1945","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1378\/chest.15-0530","article-title":"Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline","volume":"149","author":"Salisbury","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1950","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1148\/radiol.14130216","article-title":"Idiopathic pulmonary fibrosis: CT and risk of death","volume":"273","author":"Ley","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib1955","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1164\/rccm.2111053","article-title":"Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography","volume":"167","author":"Wells","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1960","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1378\/chest.13-0844","article-title":"Predicting pulmonary fibrosis disease course from past trends in pulmonary function","volume":"145","author":"Schmidt","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib1965","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00155108","article-title":"Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis","volume":"35","author":"Zappala","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib1970","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference","volume":"184","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib1975","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/thoraxjnl-2011-201184","article-title":"Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis","volume":"67","author":"Richeldi","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1980","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/thoraxjnl-2012-202640","article-title":"Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear","volume":"68","author":"Wells","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib1985","first-page":"17","article-title":"EFX et pneumopathies interstitielles diffuses\u00a0: qu\u2019en attendre et quelle place dans la prise en charge\u00a0?","volume":"19","author":"Aguilaniu","year":"2016","journal-title":"Lett Pneumol"},{"key":"10.1016\/j.rmr.2022.01.014_bib1990","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1479972309354689","article-title":"Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options","volume":"7","author":"Holland","year":"2010","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib1995","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1513\/AnnalsATS.201807-481OC","article-title":"Idiopathic pulmonary fibrosis and lung cancer. a systematic review and meta-analysis","volume":"16","author":"Brown","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2022.01.014_bib2000","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chest.2019.11.042","article-title":"Disease severity and quality of life in patients with idiopathic pulmonary fibrosis: a cross-sectional analysis of the IPF-PRO Registry","volume":"157","author":"O\u2019Brien","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1479972316674425","article-title":"Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch","volume":"14","author":"Wapenaar","year":"2017","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib2010","doi-asserted-by":"crossref","first-page":"1900281","DOI":"10.1183\/13993003.00281-2019","article-title":"King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference","volume":"54","author":"Nolan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.rmr.2022.01.014_bib2020","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2165\/11207710-000000000-00000","article-title":"Pirfenidone: in idiopathic pulmonary fibrosis","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.rmr.2022.01.014_bib2025","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.159.4.9805017","article-title":"Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study","volume":"159","author":"Raghu","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2030","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2040","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.01.014_bib2045","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3\u00a0trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2050","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1183\/09031936.00115112","article-title":"A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer","volume":"41","author":"Vancheri","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2055","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003134.pub2","article-title":"Non-steroid agents for idiopathic pulmonary fibrosis","author":"Spagnolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib2065","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1378\/chest.14-2817","article-title":"Sensitivity analyses of the change in FVC in a Phase 3\u00a0Trial of pirfenidone for idiopathic pulmonary fibrosis","volume":"148","author":"Lederer","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3\u00a0trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2075","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2080","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.chest.2018.11.008","article-title":"Efficacy of pirfenidone in the context of multiple disease progression events in patients with idiopathic pulmonary fibrosis","volume":"155","author":"Nathan","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00399-2019","article-title":"Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis","volume":"54","author":"Glassberg","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"Nathan","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2095","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000479976","article-title":"An open-label study of the long-term safety of pirfenidone in patients with Idiopathic Pulmonary Fibrosis (RECAP)","volume":"94","author":"Costabel","year":"2017","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2100","first-page":"198","article-title":"Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"31","author":"Costabel","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib2105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/resp.12207","article-title":"Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone","volume":"19","author":"Sugino","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejrad.2012.02.014","article-title":"CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"83","author":"Iwasawa","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.rmr.2022.01.014_bib2115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1164\/rccm.201406-1106LE","article-title":"Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis","volume":"191","author":"Loeh","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2120","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.rmed.2015.04.010","article-title":"Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study","volume":"109","author":"Harari","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000363064","article-title":"Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases","volume":"88","author":"Oltmanns","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1183\/09059180.00008513","article-title":"Pirfenidone: an update on clinical trial data and insights from everyday practice","volume":"23","author":"Kreuter","year":"2014","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib2135","doi-asserted-by":"crossref","first-page":"e0228390","DOI":"10.1371\/journal.pone.0228390","article-title":"Real-world experiences: efficacy and tolerability of pirfenidone in clinical practice","volume":"15","author":"Fang","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib2140","first-page":"218","article-title":"Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study","volume":"37","author":"Eaden","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib2145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.rmed.2019.08.006","article-title":"Pirfenidone in real life: a retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis","volume":"156","author":"Vancheri","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2150","doi-asserted-by":"crossref","first-page":"00084","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fmed.2017.00213","article-title":"Longitudinal \u201cReal-World\u201d outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece","volume":"4","author":"Tzouvelekis","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2160","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2169\/internalmedicine.0559-17","article-title":"The efficacy and safety of long-term pirfenidone therapy in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Ogawa","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2165","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis","volume":"23","author":"Fisher","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.rmr.2022.01.014_bib2170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1183\/09031936.00057407","article-title":"The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough","volume":"31","author":"Birring","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2175","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01157-2017","article-title":"Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis","volume":"50","author":"van Manen","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2180","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/resp.12297","article-title":"Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Valeyre","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047024","article-title":"Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials","volume":"7","author":"Jiang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib2190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12890-018-0736-z","article-title":"Pirfenidone improves survival in IPF: results from a real-life study","volume":"18","author":"Margaritopoulos","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2195","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1007\/s12325-019-01052-y","article-title":"Cardiovascular risks, bleeding risks, and clinical events from 3\u00a0Phase III trials of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"36","author":"Glassberg","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib2200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12325-014-0112-1","article-title":"Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events","volume":"31","author":"Costabel","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib2205","doi-asserted-by":"crossref","first-page":"21218","DOI":"10.1038\/s41598-020-77837-x","article-title":"Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital","volume":"10","author":"Song","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.rmr.2022.01.014_bib2210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/resp.13145","article-title":"Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia","volume":"23","author":"Uehara","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2215","series-title":"ESBRIET (pirf\u00e9nidone)\u00a0: Mise \u00e0 jour importante de s\u00e9curit\u00e9 et nouvelles recommandations concernant les risques d\u2019atteintes h\u00e9patiques d\u2019origine m\u00e9dicamenteuse - Lettre aux professionnels de sant\u00e9","year":"2020"},{"key":"10.1016\/j.rmr.2022.01.014_bib2220","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1183\/09031936.00149614","article-title":"The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis","volume":"45","author":"Grimminger","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2225","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2230","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib2235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"15","author":"Hostettler","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel mechanisms for the antifibrotic action of nintedanib","volume":"54","author":"Rangarajan","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.rmr.2022.01.014_bib2245","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2250","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.rmed.2014.04.011","article-title":"Design of the INPULSIS trials: two phase 3\u00a0trials of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"108","author":"Richeldi","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2255","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2260","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2265","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume","volume":"72","author":"Kolb","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2270","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4155\/cli.15.27","article-title":"Nintedanib: a new treatment for idiopathic pulmonary fibrosis","volume":"5","author":"Cottin","year":"2015","journal-title":"Clin Investig"},{"key":"10.1016\/j.rmr.2022.01.014_bib2275","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2280","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2285","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1874306402014010022","article-title":"Effects of nintedanib on quantitative lung fibrosis score in idiopathic pulmonary fibrosis","volume":"14","author":"Lancaster","year":"2020","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2290","article-title":"Short term Quantitative Lung Fibrosis (QLF) change predicts rapid rate of FVC decline in patients with IPF","volume":"50","author":"Goldin","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2295","article-title":"Automatic quantitative fibrosis scores at baseline is a predictor of progression in patients with IPF","volume":"50","author":"Kim","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2018.11.012","article-title":"Lung function outcomes in the INPULSIS\u00ae trials of nintedanib in idiopathic pulmonary fibrosis","volume":"146","author":"Brown","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2305","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS\u00ae trials","volume":"21","author":"Kreuter","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2310","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40169-017-0172-3","article-title":"Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clinical and translational medicine","volume":"6","author":"Toellner","year":"2017","journal-title":"Clin Trans Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2315","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pulmoe.2018.06.003","article-title":"Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre","volume":"25","author":"Bargagli","year":"2019","journal-title":"Pulmonology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2320","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000485933","article-title":"Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis","volume":"95","author":"Brunnemer","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2325","doi-asserted-by":"crossref","first-page":"00049","DOI":"10.1183\/23120541.00049-2018","article-title":"Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice","volume":"4","author":"Fletcher","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2330","doi-asserted-by":"crossref","first-page":"1702106","DOI":"10.1183\/13993003.02106-2017","article-title":"Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA","volume":"52","author":"Noth","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2335","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618800618","article-title":"Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience","volume":"12","author":"Rivera-Ortega","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib2340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pupt.2018.01.006","article-title":"Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: a real-life observational study in Greece","volume":"49","author":"Tzouvelekis","year":"2018","journal-title":"Pulm Pharm Therap"},{"key":"10.1016\/j.rmr.2022.01.014_bib2345","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00172-2019","article-title":"Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study","volume":"6","author":"Antoniou","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2350","doi-asserted-by":"crossref","first-page":"12062","DOI":"10.1038\/s41598-019-48593-4","article-title":"Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Kato","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.rmr.2022.01.014_bib2355","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2360","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01797-2018","article-title":"Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials","volume":"54","author":"Noth","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2365","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2370","first-page":"74","article-title":"Association of low body surface area with dose reduction and\/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study","volume":"36","author":"Toi","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib2375","doi-asserted-by":"crossref","first-page":"1601592","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry","volume":"49","author":"Jo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2380","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","article-title":"The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis","volume":"19","author":"Guenther","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2385","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2390","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02279-2019","article-title":"Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry","volume":"56","author":"Behr","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2395","doi-asserted-by":"crossref","first-page":"15620","DOI":"10.1038\/s41598-020-72607-1","article-title":"Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis","volume":"10","author":"Kang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.rmr.2022.01.014_bib2400","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12890-016-0308-z","article-title":"Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series","volume":"16","author":"Delanote","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2405","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0029-2019","article-title":"What have we learned from basic science studies on idiopathic pulmonary fibrosis?","volume":"28","author":"Yanagihara","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib2410","article-title":"Idiopathic pulmonary fibrosis: disease mechanisms and drug development","volume":"222","author":"Spagnolo","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib2415","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/13993003.01966-2015","article-title":"Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function","volume":"48","author":"Albera","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2420","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2213-2600(19)30255-3","article-title":"Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study","volume":"7","author":"Maher","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2425","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00408-016-9912-1","article-title":"First Data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of \u226450\u00a0% of predicted value","volume":"194","author":"Wuyts","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.rmr.2022.01.014_bib2430","doi-asserted-by":"crossref","first-page":"170047","DOI":"10.1183\/16000617.0047-2017","article-title":"Severe idiopathic pulmonary fibrosis: what can be done?","volume":"26","author":"Caminati","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib2435","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.2147\/DDDT.S179427","article-title":"Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study","volume":"12","author":"Abe","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib2440","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000487711","article-title":"A real-life multicenter national study on nintedanib in severe idiopathic pulmonary fibrosis","volume":"95","author":"Harari","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2445","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000488647","article-title":"Nintedanib in severe idiopathic pulmonary fibrosis: effectiveness through compassion","volume":"95","author":"Tzouvelekis","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2450","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12931-018-0907-8","article-title":"Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis","volume":"19","author":"Yoon","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2455","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s12325-019-00906-9","article-title":"Long-term effects and adverse events of nintedanib therapy in idiopathic pulmonary fibrosis patients with functionally advanced disease","volume":"36","author":"Barczi","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib2460","doi-asserted-by":"crossref","first-page":"262","DOI":"10.21037\/atm.2019.05.33","article-title":"A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world","volume":"7","author":"Nakamura","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2465","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1164\/rccm.201908-1510ED","article-title":"Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis. Echoes of the past. Lessons for the future","volume":"200","author":"Nathan","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2470","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s12325-020-01328-8","article-title":"Safety and efficacy of pirfenidone in advanced idiopathic pulmonary fibrosis: a nationwide post-marketing surveillance study in Korean patients","volume":"37","author":"Chung","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib2475","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","article-title":"Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis","volume":"20","author":"Richeldi","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236935","article-title":"Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity \u2264 50\u00a0%: a multi-center retrospective analysis","volume":"15","author":"Senoo","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib2485","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: the future of management for idiopathic pulmonary fibrosis?","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2490","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1183\/09031936.00198013","article-title":"Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis","volume":"45","author":"Ogura","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2495","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01060-2018","article-title":"No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone","volume":"53","author":"Richeldi","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2500","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY Trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2505","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00230-2018","article-title":"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2510","series-title":"Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial","author":"Cottin","year":"2020"},{"key":"10.1016\/j.rmr.2022.01.014_bib2515","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"King","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2520","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2525","article-title":"Efficacy and safety of macitentan in idiopathic pulmonary fibrosis: results of a prospective, randomized, double-blind, placebo-controlled trial","volume":"185","author":"Raghu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2530","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(16)30044-3","article-title":"Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2\u00a0trial","volume":"4","author":"Behr","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2535","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2540","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1164\/ajrccm.161.4.9907002","article-title":"Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival","volume":"161","author":"Douglas","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2545","first-page":"209","article-title":"Hospital-based historical cohort study of 234\u00a0histologically proven Japanese patients with IPF","volume":"16","author":"Nagai","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib2550","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1164\/ajrccm.157.4.9703022","article-title":"Idiopathic pulmonary fibrosis: predicting response to therapy and survival","volume":"157","author":"Gay","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2555","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1378\/chest.125.6.2169","article-title":"Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis","volume":"125","author":"Collard","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2560","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.rmed.2005.05.008","article-title":"Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids","volume":"100","author":"Pereira","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2565","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000108440","article-title":"Progression of fibrosis in usual interstitial pneumonia: serial evaluation of the native lung after single lung transplantation","volume":"76","author":"Grgic","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2570","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1378\/chest.121.6.2072","article-title":"Progression of idiopathic pulmonary fibrosis in native lungs after single lung transplantation","volume":"121","author":"Wahidi","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2575","first-page":"105","article-title":"Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens","volume":"12","author":"Fiorucci","year":"2008","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.rmr.2022.01.014_bib2580","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1183\/09031936.06.00032605","article-title":"Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis","volume":"28","author":"Antoniou","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2585","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/ajrccm.158.1.9709089","article-title":"Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group","volume":"158","author":"Douglas","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2590","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/thoraxjnl-2012-202403","article-title":"Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial","volume":"68","author":"Shulgina","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2595","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.2020.22960","article-title":"Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: the EME-TIPAC Randomized Clinical Trial","volume":"324","author":"Wilson","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.rmr.2022.01.014_bib2600","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1001\/jama.2021.4956","article-title":"Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial","volume":"325","author":"Martinez","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.rmr.2022.01.014_bib2605","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","article-title":"Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial","volume":"178","author":"Raghu","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2610","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.chest.2019.04.015","article-title":"Association of angiotensin modulators with the course of idiopathic pulmonary fibrosis","volume":"156","author":"Kreuter","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2615","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2620","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.01.014_bib2625","first-page":"3661968","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2630","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","article-title":"TOLLIP, MUC5B, and the response to N-Acetylcysteine among individuals with idiopathic pulmonary fibrosis","volume":"192","author":"Oldham","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2635","article-title":"ARTEMIS-IPF: a placebo-controlled trial of ambrisentan in idiopathic pulmonary fibrosis","volume":"185","author":"Raghu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2640","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","article-title":"A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis","volume":"186","author":"Noth","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2645","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1183\/13993003.02087-2015","article-title":"Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis","volume":"47","author":"Kreuter","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2650","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.200304-597OC","article-title":"A study of the cough reflex in idiopathic pulmonary fibrosis","volume":"168","author":"Hope-Gill","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2655","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.athoracsur.2007.04.096","article-title":"Lung transplantation for idiopathic pulmonary fibrosis","volume":"84","author":"Mason","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib2660","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.transproceed.2008.10.042","article-title":"Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15\u00a0years","volume":"41","author":"Keating","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.rmr.2022.01.014_bib2665","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0022-5223(03)00600-7","article-title":"Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis","volume":"126","author":"Thabut","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib2670","series-title":"Adult Lung Transplantation Statistics","author":"The International Society for Heart and Lung Transplantation","year":"2015"},{"key":"10.1016\/j.rmr.2022.01.014_bib2675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.rmr.2022.01.014_bib2680","doi-asserted-by":"crossref","first-page":"e0233732","DOI":"10.1371\/journal.pone.0233732","article-title":"Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib2685","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000114246","article-title":"Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"76","author":"Nathan","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2690","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.healun.2014.09.004","article-title":"Effect of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis after lung transplantation: an analysis of the United Network of Organ Sharing registry","volume":"34","author":"Hayes","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.rmr.2022.01.014_bib2695","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40248-018-0129-4","article-title":"Effect of pirfenidone on wound healing in lung transplant patients","volume":"13","author":"Mortensen","year":"2018","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2700","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.312","article-title":"Safety of nintedanib before lung transplant: an Italian case series","volume":"6","author":"Balestro","year":"2018","journal-title":"Respir Case Rep"},{"key":"10.1016\/j.rmr.2022.01.014_bib2705","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1164\/rccm.202006-2441LE","article-title":"Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study","volume":"202","author":"Esposito","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2710","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1164\/rccm.202007-2794OC","article-title":"Outcome of hospitalization for COVID-19\u00a0in patients with interstitial lung disease. An International multicenter study","volume":"202","author":"Drake","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2715","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1164\/rccm.202007-2638LE","article-title":"Risk factors for mortality after COVID-19\u00a0in patients with preexisting interstitial lung disease","volume":"203","author":"Gallay","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2720","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.chest.2018.06.038","article-title":"Treatment of interstitial lung disease associated cough: CHEST Guideline and Expert Panel Report","volume":"154","author":"Birring","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2725","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s41030-021-00162-9","article-title":"Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3\u00a0Antagonist, in a Randomized, Placebo-Controlled Clinical Trial","volume":"7","author":"Martinez","year":"2021","journal-title":"Pulmonary therapy"},{"key":"10.1016\/j.rmr.2022.01.014_bib2730","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/thx.2008.098699","article-title":"Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis","volume":"63","author":"Horton","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2735","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-157-6-201209180-00003","article-title":"Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial","volume":"157","author":"Horton","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2740","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1745-9974-10-4","article-title":"Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study","volume":"10","author":"Kilduff","year":"2014","journal-title":"Coug"},{"key":"10.1016\/j.rmr.2022.01.014_bib2745","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/thoraxjnl-2018-212102","article-title":"Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis","volume":"74","author":"Dutta","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2750","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.01.014_bib2755","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/resp.12989","article-title":"Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry","volume":"22","author":"Glaspole","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2760","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","article-title":"Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry","volume":"18","author":"Kreuter","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2765","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/resp.12945","article-title":"A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease","volume":"22","author":"Khadawardi","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2770","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/thoraxjnl-2012-202040","article-title":"Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature","volume":"68","author":"Bajwah","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2775","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12890-018-0651-3","article-title":"Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review","volume":"18","author":"Carvajalino","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2780","doi-asserted-by":"crossref","first-page":"00347","DOI":"10.1183\/23120541.00347-2020","article-title":"Factor analysis identifies three separate symptom clusters in idiopathic pulmonary fibrosis","volume":"6","author":"Sepp\u00e4l\u00e4","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2785","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00408-015-9703-0","article-title":"Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis","volume":"193","author":"Vainshelboim","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.rmr.2022.01.014_bib2790","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000367899","article-title":"Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis","volume":"88","author":"Vainshelboim","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2795","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000354112","article-title":"Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis--a review","volume":"86","author":"Kenn","year":"2013","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2800","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"10","author":"Dowman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib2805","doi-asserted-by":"crossref","first-page":"00045","DOI":"10.1183\/23120541.00045-2019","article-title":"Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias","volume":"5","author":"Wallaert","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib2810","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12890-017-0476-5","article-title":"Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study","volume":"17","author":"Tonelli","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2815","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thorax.57.11.939","article-title":"A systematic review of the use of opioids in the management of dyspnoea","volume":"57","author":"Jennings","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2820","doi-asserted-by":"crossref","first-page":"30629","DOI":"10.3402\/ecrj.v3.30629","article-title":"Opioids: an unexplored option for treatment of dyspnea in IPF","volume":"3","author":"Kohberg","year":"2016","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2825","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1191\/0269216305pm998oa","article-title":"Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis","volume":"19","author":"Allen","year":"2005","journal-title":"Palliat Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2830","doi-asserted-by":"crossref","first-page":"1801278","DOI":"10.1183\/13993003.01278-2018","article-title":"Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study","volume":"52","author":"Bajwah","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2835","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-93-3-391","article-title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial","volume":"93","author":"Nocturnal Oxygen Therapy Trial Group","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2840","first-page":"681","article-title":"Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party","volume":"1","author":"Medical Research Council Working Party","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.01.014_bib2845","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1164\/rccm.202009-3608ST","article-title":"Home oxygen therapy for adults with chronic lung disease. An Official American Thoracic Society Clinical Practice Guideline","volume":"202","author":"Jacobs","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2850","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1378\/chest.102.2.542","article-title":"Increased exercise capacity in hypoxemic patients after long-term oxygen therapy","volume":"102","author":"Morrison","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2855","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1183\/09031936.00190710","article-title":"Ambulatory oxygen in interstitial lung disease","volume":"38","author":"Visca","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2860","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1183\/09031936.00007712","article-title":"Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit?","volume":"40","author":"Frank","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2865","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/resp.13829","article-title":"Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation","volume":"25","author":"Arizono","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2870","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.rmed.2013.05.015","article-title":"Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia","volume":"107","author":"Nishiyama","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2875","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2880","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00421-2019","article-title":"Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey","volume":"54","author":"Lim","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2885","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01563-2020","article-title":"Moderate resting hypoxaemia in fibrotic interstitial lung disease","volume":"57","author":"Khor","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2890","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chest.2020.01.049","article-title":"Ambulatory oxygen in fibrotic interstitial lung disease: a pilot, randomized, triple-blinded, sham-controlled trial","volume":"158","author":"Khor","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2895","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.rmed.2018.03.025","article-title":"The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease","volume":"138","author":"Ramadurai","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2900","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/thx.2007.088070","article-title":"Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease","volume":"63","author":"Holland","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2905","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1440-1843.2007.01205.x","article-title":"Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis","volume":"13","author":"Nishiyama","year":"2008","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib2910","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4187\/respcare.03180","article-title":"Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program","volume":"59","author":"Gaunaurd","year":"2014","journal-title":"Respir Care"},{"key":"10.1016\/j.rmr.2022.01.014_bib2915","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","article-title":"The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial","volume":"72","author":"Dowman","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2920","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/HCR.0000000000000544","article-title":"Clinical Improvement and effectiveness of exercise-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: a brief analytical review","volume":"41","author":"Vainshelboim","year":"2021","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"10.1016\/j.rmr.2022.01.014_bib2925","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.rmed.2013.11.016","article-title":"Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study","volume":"108","author":"Ryerson","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2930","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1378\/chest.08-1458","article-title":"Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response","volume":"135","author":"Ferreira","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib2935","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rmed.2011.11.014","article-title":"Predictors of benefit following pulmonary rehabilitation for interstitial lung disease","volume":"106","author":"Holland","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2940","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000315475","article-title":"Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease","volume":"81","author":"Kozu","year":"2011","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib2945","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1183\/09031936.00081512","article-title":"Effects of in-patient pulmonary rehabilitation in patients with interstitial lung disease","volume":"42","author":"Huppmann","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2950","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0761-8425(09)72584-7","article-title":"Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis","volume":"26","author":"Rammaert","year":"2009","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2022.01.014_bib2955","series-title":"Classification internationale du fonctionnement, du handicap et de la sant\u00e9: CIF Gen\u00e8ve","author":"Organisation Mondiale de la Sant\u00e9","year":"2001"},{"key":"10.1016\/j.rmr.2022.01.014_bib2960","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8498603","article-title":"Pulmonary rehabilitation for exercise tolerance and quality of life in IPF patients: a systematic review and meta-analysis","volume":"2019","author":"Yu","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.rmr.2022.01.014_bib2965","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12890-015-0145-5","article-title":"The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study","volume":"15","author":"Sampson","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2970","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12890-016-0171-y","article-title":"Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients\u2019 perspectives of the disease and treatment","volume":"16","author":"Russell","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib2975","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1183\/13993003.01566-2015","article-title":"The lived experience with idiopathic pulmonary fibrosis: a qualitative study","volume":"47","author":"Overgaard","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib2980","first-page":"26","article-title":"O\u00f9 meurent les patients atteints de fibrose pulmonaire idiopathique\u00a0?","volume":"127","author":"Taill\u00e9","year":"2015","journal-title":"Info Respir"},{"key":"10.1016\/j.rmr.2022.01.014_bib2985","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/thoraxjnl-2015-207439","article-title":"End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study","volume":"71","author":"Ahmadi","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib2990","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12904-016-0158-8","article-title":"End-of-life care of patients with idiopathic pulmonary fibrosis","volume":"15","author":"Rajala","year":"2016","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.rmr.2022.01.014_bib2995","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/thoraxjnl-2014-206583","article-title":"Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention","volume":"70","author":"Bajwah","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib3000","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0140-6736(10)61115-4","article-title":"Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial","volume":"376","author":"Abernethy","year":"2010","journal-title":"Lance"},{"key":"10.1016\/j.rmr.2022.01.014_bib3005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.hrtlng.2016.10.002","article-title":"The palliative care needs of patients with idiopathic pulmonary fibrosis: a qualitative study of patients and family caregivers","volume":"46","author":"Lindell","year":"2017","journal-title":"Heart Lung"},{"key":"10.1016\/j.rmr.2022.01.014_bib3010","article-title":"Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations","volume":"5","author":"Lindell","year":"2018","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib3015","series-title":"Assistance Publique\u2013H\u00f4pitaux de Paris. Impact des soins palliatifs syst\u00e9matiques sur la qualit\u00e9 de vie, dans la fibrose pulmonaire idiopathique avanc\u00e9e","author":"Duchemann","year":"2017"},{"key":"10.1016\/j.rmr.2022.01.014_bib3020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1378\/chest.13-2424","article-title":"Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study","volume":"147","author":"Brown","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3025","doi-asserted-by":"crossref","first-page":"10742","DOI":"10.1038\/s41598-020-67598-y","article-title":"Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Zhuang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.rmr.2022.01.014_bib3030","doi-asserted-by":"crossref","first-page":"170050","DOI":"10.1183\/16000617.0050-2017","article-title":"Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis","volume":"26","author":"Kondoh","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib3035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12931-016-0400-1","article-title":"Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis","volume":"17","author":"Kakugawa","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib3040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12890-019-0880-0","article-title":"Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience","volume":"19","author":"Kawamura","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.resinv.2020.02.004","article-title":"Predictors of acute exacerbation in biopsy-proven idiopathic pulmonary fibrosis","volume":"58","author":"Kishaba","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.rmr.2022.01.014_bib3050","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1183\/09031936.00122213","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure","volume":"43","author":"Johannson","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/thoraxjnl-2017-209967","article-title":"Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis","volume":"73","author":"Ses\u00e9","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib3060","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1183\/09031936.00127311","article-title":"Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses","volume":"38","author":"Morawiec","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12890-019-0830-x","article-title":"Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)","volume":"19","author":"Naccache","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3070","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1164\/rccm.201110-1842ED","article-title":"Idiopathic pulmonary fibrosis: increased survival with \u201cgastroesophageal reflux therapy\u201d: fact or fallacy?","volume":"184","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3075","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1164\/rccm.201909-1818OC","article-title":"Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial","volume":"201","author":"Kondoh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3080","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1378\/chest.128.3.1475","article-title":"Anticoagulant therapy for idiopathic pulmonary fibrosis","volume":"128","author":"Kubo","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3085","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/03007995.2019.1565530","article-title":"Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation","volume":"35","author":"Vianello","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rmr.2022.01.014_bib3090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.rmed.2017.03.026","article-title":"Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study","volume":"126","author":"Furuya","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3095","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1513\/AnnalsATS.201504-210AW","article-title":"Time for prevention of idiopathic pulmonary fibrosis exacerbation","volume":"12","author":"Richeldi","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2022.01.014_bib3100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12890-017-0437-z","article-title":"Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study","volume":"17","author":"Kawamura","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3105","first-page":"527","article-title":"Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure","volume":"93","author":"Trudzinski","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3110","doi-asserted-by":"crossref","first-page":"1901760","DOI":"10.1183\/13993003.01760-2019","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation","volume":"55","author":"Kreuter","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3115","series-title":"EMC Appareil locomoteur [Internet]","article-title":"Ost\u00e9oporose cortisonique","author":"Marcelli","year":"2011"},{"key":"10.1016\/j.rmr.2022.01.014_bib3120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1378\/chest.120.1.209","article-title":"Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure","volume":"120","author":"Blivet","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.06.00114004","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features","volume":"27","author":"Kim","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0025-7753(03)73856-1","article-title":"[Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit. A study of 20\u00a0cases]","volume":"121","author":"Molina-Molina","year":"2003","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.rmr.2022.01.014_bib3135","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.2104038","article-title":"Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit","volume":"166","author":"Saydain","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3140","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/thx.54.5.390","article-title":"Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis","volume":"54","author":"Nava","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib3145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1378\/chest.120.1.213","article-title":"Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure","volume":"120","author":"Stern","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3150","first-page":"117","article-title":"Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis","volume":"11","author":"Al-Hameed","year":"2004","journal-title":"Can Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3155","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s00134-001-1150-0","article-title":"Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis","volume":"27","author":"Fumeaux","year":"2001","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000225932","article-title":"Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis","volume":"79","author":"Mollica","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib3165","first-page":"102","article-title":"Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis","volume":"11","author":"Rangappa","year":"2009","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.rmr.2022.01.014_bib3170","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.rmed.2008.06.003","article-title":"Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit","volume":"102","author":"Mallick","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2015.12.005","article-title":"The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis","volume":"111","author":"Rush","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtcvs.2013.06.039","article-title":"Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia","volume":"147","author":"Gaudry","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib3185","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2169\/internalmedicine.49.3222","article-title":"Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"49","author":"Yokoyama","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13546-012-0642-y","article-title":"Fibrose pulmonaire\u00a0: dans quels cas et sur quels crit\u00e8res envisager une admission en r\u00e9animation\u00a0?","author":"Mullier","year":"2013","journal-title":"R\u00e9animation"},{"key":"10.1016\/j.rmr.2022.01.014_bib3195","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3200","first-page":"148","article-title":"Pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Nathan","year":"2012","journal-title":"Eur Respir Mon"},{"key":"10.1016\/j.rmr.2022.01.014_bib3205","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1183\/09031936.00107206","article-title":"Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant","volume":"30","author":"Shorr","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3210","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1378\/chest.129.3.746","article-title":"Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis","volume":"129","author":"Lettieri","year":"2006","journal-title":"Ches"},{"key":"10.1016\/j.rmr.2022.01.014_bib3215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1183\/09031936.00115511","article-title":"Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis","volume":"40","author":"Judge","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3220","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.rmed.2008.03.022","article-title":"Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis","volume":"102","author":"Nathan","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3225","article-title":"Doppler echocardiography-right heart catheterization relationships in patients with idiopathic pulmonary fibrosis and suspected pulmonary hypertension","volume":"14","author":"Swanson","year":"2008","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.rmr.2022.01.014_bib3230","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1164\/rccm.200210-1130OC","article-title":"Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease","volume":"167","author":"Arcasoy","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3235","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1148\/radiol.2492080269","article-title":"The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension","volume":"249","author":"Devaraj","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib3240","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/rccm.200510-1545OC","article-title":"Brain natriuretic peptide is a prognostic parameter in chronic lung disease","volume":"173","author":"Leuchte","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3245","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1378\/chest.07-2488","article-title":"Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis","volume":"133","author":"Zisman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3250","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3255","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3260","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3265","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","article-title":"Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial","volume":"42","author":"Raghu","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3270","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.rmed.2016.11.003","article-title":"Idiopathic interstitial pneumonia-associated pulmonary hypertension: a target for therapy?","volume":"122","author":"Nathan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3275","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3280","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.01.014_bib3285","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.vph.2006.01.013","article-title":"A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease","volume":"44","author":"Madden","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3290","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1378\/chest.06-2101","article-title":"Sildenafil improves walk distance in idiopathic pulmonary fibrosis","volume":"131","author":"Collard","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3295","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3300","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141911","article-title":"Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias","volume":"10","author":"Hoeper","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib3310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3315","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A randomized, double-blind, placebo-controlled study of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis","volume":"158","author":"Nathan","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3320","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3325","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00101212","article-title":"Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients","volume":"42","author":"Savarino","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3330","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1183\/09031936.00099910","article-title":"Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis","volume":"39","author":"Noth","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3335","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1183\/13993003.01796-2015","article-title":"Hiatal hernia on thoracic computed tomography in pulmonary fibrosis","volume":"48","author":"Tossier","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3340","doi-asserted-by":"crossref","first-page":"1802412","DOI":"10.1183\/13993003.02412-2018","article-title":"In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality","volume":"53","author":"Mackintosh","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3345","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.chest.2019.03.042","article-title":"Gastroesophageal reflux disease and idiopathic pulmonary fibrosis: no data for supporting a relationship after a systematic review","volume":"156","author":"Corrao","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3350","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1164\/ajrccm.158.6.9804105","article-title":"Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis","volume":"158","author":"Tobin","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3355","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jtcvs.2006.09.085","article-title":"Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation","volume":"133","author":"Sweet","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib3360","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.chest.2018.07.038","article-title":"Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis","volume":"155","author":"Bedard Methot","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3365","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.chest.2019.04.014","article-title":"Response","volume":"156","author":"Lacasse","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3370","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.amjmed.2009.07.033","article-title":"Does chronic microaspiration cause idiopathic pulmonary fibrosis?","volume":"123","author":"Lee","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3375","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtcvs.2005.10.014","article-title":"Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation","volume":"131","author":"Linden","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib3380","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2213-2600(18)30301-1","article-title":"Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2\u00a0trial","volume":"6","author":"Raghu","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3385","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3390","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000468546","article-title":"Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis who received pirfenidone","volume":"93","author":"Kreuter","year":"2017","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib3395","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12931-018-0866-0","article-title":"Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials","volume":"19","author":"Costabel","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib3400","doi-asserted-by":"crossref","first-page":"1800376","DOI":"10.1183\/13993003.00376-2018","article-title":"The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies","volume":"51","author":"Tran","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3405","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.chest.2020.08.2080","article-title":"Effectiveness of proton pump inhibitors in idiopathic pulmonary fibrosis: a population-based cohort study","volume":"159","author":"Tran","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3410","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3415","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S2213-2600(16)00067-9","article-title":"Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis","volume":"4","author":"Kreuter","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3420","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3425","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.resinv.2013.09.002","article-title":"Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis","volume":"52","author":"Arai","year":"2014","journal-title":"Respir Investig"},{"key":"10.1016\/j.rmr.2022.01.014_bib3430","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1164\/rccm.201612-2492OC","article-title":"Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosis","volume":"196","author":"Cottin","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3435","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1148\/radiol.2511080917","article-title":"Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings","volume":"251","author":"Akira","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.rmr.2022.01.014_bib3440","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2466-14-104","article-title":"An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features","volume":"14","author":"Inomata","year":"2014","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3445","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ejrad.2015.01.015","article-title":"Multiple, thin-walled cysts are one of the HRCT features of airspace enlargement with fibrosis","volume":"84","author":"Watanabe","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3450","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/jclinpath-2012-201338","article-title":"Smoking-related interstitial fibrosis (SRIF): pathologic findings and distinction from other chronic fibrosing lung diseases","volume":"66","author":"Katzenstein","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3455","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.08-2306","article-title":"Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension","volume":"136","author":"Mejia","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3460","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1183\/09031936.05.00021005","article-title":"Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity","volume":"26","author":"Cottin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3465","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/resp.13231","article-title":"Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema","volume":"23","author":"Jacob","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib3470","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00379-2017","article-title":"Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis","volume":"50","author":"Jacob","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3475","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1183\/09031936.00038709","article-title":"Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome","volume":"35","author":"Cottin","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3480","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.rmed.2009.02.001","article-title":"Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis","volume":"103","author":"Akagi","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3485","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1183\/09031936.00114010","article-title":"Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema","volume":"38","author":"Schmidt","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3490","doi-asserted-by":"crossref","first-page":"1801655","DOI":"10.1183\/13993003.01655-2018","article-title":"Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials","volume":"53","author":"Cottin","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3495","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/thx.56.6.482","article-title":"A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis","volume":"56","author":"Clark","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib3500","first-page":"213","article-title":"[Assessment of sleep with polysomnography in patients with interstitial lung disease]","volume":"54","author":"Aydogdu","year":"2006","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.rmr.2022.01.014_bib3505","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00408-007-9004-3","article-title":"Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis","volume":"185","author":"Mermigkis","year":"2007","journal-title":"Lung"},{"key":"10.1016\/j.rmr.2022.01.014_bib3510","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.rmed.2018.12.018","article-title":"Quality of life in idiopathic pulmonary fibrosis: the impact of sleep disordered breathing","volume":"147","author":"Bosi","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3515","doi-asserted-by":"crossref","first-page":"1601934","DOI":"10.1183\/13993003.01934-2016","article-title":"Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis","volume":"49","author":"Gille","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3520","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1378\/chest.08-2776","article-title":"Obstructive sleep apnea is common in idiopathic pulmonary fibrosis","volume":"136","author":"Lancaster","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3525","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00408-017-0031-4","article-title":"OSA and prolonged oxygen desaturation during sleep are strong predictors of poor outcome in IPF","volume":"195","author":"Bosi","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.rmr.2022.01.014_bib3530","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/resp.13549","article-title":"Nocturnal hypoxaemia is associated with adverse outcomes in interstitial lung disease","volume":"24","author":"Troy","year":"2019","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib3535","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.chest.2020.04.067","article-title":"CPAP adherence, mortality, and progression-free survival in interstitial lung disease and OSA","volume":"158","author":"Adegunsoye","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3540","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.rmr.2010.05.011","volume":"27","year":"2010","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2022.01.014_bib3545","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11325-014-1033-6","article-title":"Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Mermigkis","year":"2015","journal-title":"Sleep Breath"},{"key":"10.1016\/j.rmr.2022.01.014_bib3550","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1164\/ajrccm.161.1.9906062","article-title":"Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study","volume":"161","author":"Hubbard","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3555","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41598-021-82182-8","article-title":"A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis","volume":"11","author":"Song","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.rmr.2022.01.014_bib3560","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1513\/AnnalsATS.201808-510OC","article-title":"Outcomes of older patients with pulmonary fibrosis and non-small cell lung cancer","volume":"16","author":"Whittaker Brown","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2022.01.014_bib3565","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12931-017-0605-y","article-title":"Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses","volume":"18","author":"Guyard","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib3570","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/JTO.0000000000000209","article-title":"Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47\u00a0Western patients","volume":"9","author":"Girard","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3575","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.resinv.2019.06.001","article-title":"Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia","volume":"57","author":"Ogura","year":"2019","journal-title":"Respir Investig"},{"key":"10.1016\/j.rmr.2022.01.014_bib3580","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccm.2011.12.005","article-title":"Idiopathic pulmonary fibrosis: phenotypes and comorbidities","volume":"33","author":"Fell","year":"2012","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3585","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.athoracsur.2016.05.094","article-title":"Effect of perioperative pirfenidone treatment in lung cancer patients with idiopathic pulmonary fibrosis","volume":"102","author":"Iwata","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib3590","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12931-016-0398-4","article-title":"A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711\u00a0L (PEOPLE Study)","volume":"17","author":"Iwata","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib3595","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00595-020-01978-9","article-title":"Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis","volume":"50","author":"Sekihara","year":"2020","journal-title":"Surg Today"},{"key":"10.1016\/j.rmr.2022.01.014_bib3600","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00595-019-01923-5","article-title":"Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis","volume":"50","author":"Kanayama","year":"2020","journal-title":"Surg Today"},{"key":"10.1016\/j.rmr.2022.01.014_bib3605","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1111\/1759-7714.13675","article-title":"Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: a retrospective cohort study","volume":"11","author":"Yamamoto","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.rmr.2022.01.014_bib3610","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2013.09.050","article-title":"Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer","volume":"147","author":"Sato","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rmr.2022.01.014_bib3615","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.lungcan.2013.08.024","article-title":"Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis","volume":"82","author":"Yamaguchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2022.01.014_bib3620","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jtho.2020.02.005","article-title":"A primer on interstitial lung disease and thoracic radiation","volume":"15","author":"Goodman","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3625","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2010.04.014","article-title":"The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias","volume":"71","author":"Minegishi","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2022.01.014_bib3630","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2019.09.020","article-title":"A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)","volume":"138","author":"Asahina","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2022.01.014_bib3635","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1111\/cas.14217","article-title":"Phase II study of nab-paclitaxel+carboplatin for patients with non-small-cell lung cancer and interstitial lung disease","volume":"110","author":"Kenmotsu","year":"2019","journal-title":"Cancer science"},{"key":"10.1016\/j.rmr.2022.01.014_bib3640","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00280-014-2590-x","article-title":"The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease","volume":"74","author":"Shimizu","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2022.01.014_bib3650","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","article-title":"Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm phase II trial","volume":"134","author":"Fujimoto","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2022.01.014_bib3655","article-title":"A phase II study of atezolizumab for pretreated advanced\/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936\/AMBITIOUS study","volume":"12","author":"Ikeda","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3660","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/JTO.0b013e3182103d3c","article-title":"The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias","volume":"6","author":"Minegishi","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3665","first-page":"1175","article-title":"Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease","volume":"33","author":"Yoshida","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib3670","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s10147-013-0554-5","article-title":"Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis","volume":"19","author":"Watanabe","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3675","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12032-009-9283-z","article-title":"Interstitial lung disease in patients with small cell lung cancer","volume":"27","author":"Miyazaki","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.rmr.2022.01.014_bib3680","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cllc.2011.11.001","article-title":"Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer","volume":"13","author":"Togashi","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.rmr.2022.01.014_bib3685","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3690","first-page":"17","article-title":"IPF, comorbidities and management implications","volume":"32","author":"Vancheri","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib3695","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.rmed.2014.01.008","article-title":"How does comorbidity influence survival in idiopathic pulmonary fibrosis?","volume":"108","author":"Hyldgaard","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3700","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/thoraxjnl-2013-203740","article-title":"Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study","volume":"69","author":"Navaratnam","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2022.01.014_bib3705","first-page":"294","article-title":"Are idiopathic pulmonary fibrosis patients more anxious and depressive than patient's with other interstitial lung disease?","volume":"36","author":"Yaln\u0131z","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.rmr.2022.01.014_bib3710","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/resp.12360","article-title":"Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease","volume":"19","author":"Holland","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2022.01.014_bib3715","doi-asserted-by":"crossref","first-page":"e0184300","DOI":"10.1371\/journal.pone.0184300","article-title":"Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2022.01.014_bib3720","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2169\/internalmedicine.56.7019","article-title":"Depression is significantly associated with the health status in patients with idiopathic pulmonary fibrosis","volume":"56","author":"Matsuda","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3725","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(19)31785-4","article-title":"Management of frailty: opportunities, challenges, and future directions","volume":"394","author":"Dent","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.01.014_bib3730","doi-asserted-by":"crossref","first-page":"1900647","DOI":"10.1183\/13993003.00647-2019","article-title":"Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes","volume":"55","author":"Guler","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3735","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3111\/13696998.2012.680553","article-title":"Burden of illness in idiopathic pulmonary fibrosis","volume":"15","author":"Collard","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.rmr.2022.01.014_bib3740","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3745","doi-asserted-by":"crossref","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.01.014_bib3750","doi-asserted-by":"crossref","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","article-title":"Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)","volume":"57","author":"Nasser","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3755","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1159\/000509556","article-title":"Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers","volume":"99","author":"Faverio","year":"2020","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2022.01.014_bib3760","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.rmr.2022.01.014_bib3765","doi-asserted-by":"crossref","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3770","doi-asserted-by":"crossref","first-page":"1800692","DOI":"10.1183\/13993003.00692-2018","article-title":"What's in a name? That which we call IPF, by any other name would act the same","volume":"51","author":"Wells","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3775","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3780","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3785","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2\u00a0trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3790","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3795","first-page":"2004587","article-title":"Effects of nintedanib by inclusion criteria for progression of interstitial lung disease","author":"Maher","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3800","article-title":"Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial","author":"Flaherty","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2011.11.005","article-title":"Telomeres and disease: an overview","volume":"730","author":"Armanios","year":"2012","journal-title":"Mutat Res"},{"key":"10.1016\/j.rmr.2022.01.014_bib3810","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7837","article-title":"Loss-of-function mutations in the RNA biogenesis factor NAF1\u00a0predispose to pulmonary fibrosis-emphysema","volume":"8","author":"Stanley","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.rmr.2022.01.014_bib3815","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/ng.3278","article-title":"Exome sequencing links mutations in PARN and RTEL1\u00a0with familial pulmonary fibrosis and telomere shortening","volume":"47","author":"Stuart","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.rmr.2022.01.014_bib3820","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1183\/09031936.00040115","article-title":"Heterozygous RTEL1\u00a0mutations are associated with familial pulmonary fibrosis","volume":"46","author":"Kannengiesser","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3825","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/504639","article-title":"ELMOD2\u00a0is a candidate gene for familial idiopathic pulmonary fibrosis","volume":"79","author":"Hodgson","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.rmr.2022.01.014_bib3830","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1183\/09031936.06.00044006","article-title":"Neurofibromatosis-associated lung disease: a case series and literature review","volume":"29","author":"Zamora","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.01.014_bib3835","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1378\/chest.12-2502","article-title":"Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1","volume":"144","author":"Hamvas","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2022.01.014_bib3840","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1097-2765(00)80170-7","article-title":"Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3\u00a0adaptor","volume":"3","author":"Dell\u2019Angelica","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.rmr.2022.01.014_bib3845","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ajhg.2013.10.013","article-title":"Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis","volume":"93","author":"Mercier","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.rmr.2022.01.014_bib3850","first-page":"209","article-title":"Hospital-based historical cohort study of 234\u00a0histologically proven Japanese patients with IPF","volume":"16","author":"Nagai","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:24:47Z","timestamp":1760106287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842522000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":571,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0761842522000353"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2022.01.014","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique\u00a0\u2013\u00a0Actualisation 2021. Version int\u00e9grale","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2022.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}